Dopamine and Huntington's disease. (Q38379277)

2 September 2017

title

Dopamine and Huntington's disease. (English)

1 reference

2 September 2017

0 references

Laetitia C Schwab

1 reference

2 September 2017

Shady N Garas

1 reference

2 September 2017

Janelle Drouin-Ouellet

1 reference

2 September 2017

Sarah L Mason

1 reference

2 September 2017

Simon R Stott

1 reference

2 September 2017

Roger A Barker

1 reference

2 September 2017

publication date

16 March 2015

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

2 September 2017

published in

1 reference

2 September 2017

1 reference

2 September 2017

1 reference

2 September 2017

page(s)

445-458

1 reference

Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Huntington disease: natural history, biomarkers and prospects for therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Mechanisms of neurodegeneration in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Mutant huntingtin is present in neuronal grafts in Huntington disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Impaired dopamine release and uptake in R6/1 Huntington's disease model mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Motor function and dopamine release measurements in transgenic Huntington's disease model rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Predictive test for Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Chemical pathology of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The neurobiology of dopamine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Structure and function of dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Role of dopamine D2 receptors in human reinforcement learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Mesocortical dopamine modulation of executive functions: beyond working memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The neural circuitry of executive functions in healthy subjects and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Chemistry of the mind: neurochemical modulation of prefrontal cortical function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The physiology, signaling, and pharmacology of dopamine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The basal ganglia: focused selection and inhibition of competing motor programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The functional anatomy of basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Evidence for dysfunction of the nigrostriatal pathway in the R6/1 line of transgenic Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A quantitative investigation of the substantia nigra in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Decreased striatal monoaminergic terminals in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Dopaminergic signaling and striatal neurodegeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas A PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Huntington's disease progression. PET and clinical observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Hypothalamic involvement in Huntington's disease: an in vivo PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Extrastriatal dopamine D(2) receptor binding in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Animal models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Huntington's Disease: Can Mice Lead the Way to Treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Neurochemical changes following the administration of depleters of biogenic monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Long-term effects of tetrabenazine in hyperkinetic movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Tetrabenazine treatment for Huntington's disease-associated chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Short-term effects of tetrabenazine on chorea associated with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The long-term effect of tetrabenazine in the management of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The gait abnormality of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A Europe-wide assessment of current medication choices in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Olanzapine for Huntington's disease: an open label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Effects of bromocriptine on central dopaminergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Bromocriptine in Huntington Chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Acute treatment of Huntington's chorea with lisuride

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Levodopa and Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Letter: Huntington's chorea and levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Levodopa in Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Emerging drug therapies in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

In vivo pharmacology of the dopaminergic stabilizer pridopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Schizophrenia: from dopamine to glutamate and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Clinical neurogenetics: huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

High-dose olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1025383

10.1586/14737175.2015.1025383

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference